TY - JOUR
T1 - Exposure Definition in Case–Control Studies of Cervical Cancer Screening
T2 - A Systematic Literature Review
AU - Castanon, Alejandra
AU - Kamineni, Aruna
AU - Elfstrom, K. Miriam
AU - Lim, Anita W.W.
AU - Sasieni, Peter
N1 - Funding Information:
A.W.W. Lim reports non-financial support from Copan Italia S.p.A and nonfinancial support from Roche Diagnostics outside the submitted work. P. Sasieni reports grants from Cancer Research UK during the conduct of the study as well as grants from Public Health England and NIHR and personal fees from Roche outside the submitted work. No disclosures were reported by the other authors.
Funding Information:
The authors were brought together through the International Cancer Screening Network Cervical Working Group. The authors wish to thank this group for their input on the manuscript concept during a presentation at the 2019 International Cancer Screening Network Conference in Rotterdam, the Netherlands. Research reported in this publication was supported by a Cancer Research UK programme grant awarded to P. Sasieni (C8162/A27047), and by the NCI of the NIH awarded to A. Kamineni under award number (1UM1CA221940).
Publisher Copyright:
©2021 The Authors; Published by the American Association for Cancer Research
PY - 2021/12
Y1 - 2021/12
N2 - The first step in evaluating the effectiveness of cervical screening is defining exposure to screening. Our aim was to describe the spectrum of screening exposure definitions used in studies of the effectiveness of cervical screening. This systematic review included case-control studies in a population-based screening setting. Outcome was incidence of cervical cancer. Three electronic databases were searched from January 1, 2012 to December 6, 2018. Articles prior to 2012 were identified from a previous review. The qualitative synthesis focused on describing screening exposure definitions reported in the literature and the methodologic differences that could have an impact on the association between screening and cervical cancer. Forty-one case–control studies were included. Six screening exposure definitions were identified. Cervical cancer risk on average decreased by 66% when screening exposure was defined as ever tested, by 77% by time since last negative test, and by 79% after two or more previous tests. Methodologic differences included composition of the reference group and whether diagnostic and/or symptomatic tests were excluded from the analysis. Consensus guidelines to standardize exposure definitions are needed to ensure evaluations of cervical cancer screening can accurately measure the impact of transitioning from cytology to human papillomavirus–based screening and to allow comparisons between programs.
AB - The first step in evaluating the effectiveness of cervical screening is defining exposure to screening. Our aim was to describe the spectrum of screening exposure definitions used in studies of the effectiveness of cervical screening. This systematic review included case-control studies in a population-based screening setting. Outcome was incidence of cervical cancer. Three electronic databases were searched from January 1, 2012 to December 6, 2018. Articles prior to 2012 were identified from a previous review. The qualitative synthesis focused on describing screening exposure definitions reported in the literature and the methodologic differences that could have an impact on the association between screening and cervical cancer. Forty-one case–control studies were included. Six screening exposure definitions were identified. Cervical cancer risk on average decreased by 66% when screening exposure was defined as ever tested, by 77% by time since last negative test, and by 79% after two or more previous tests. Methodologic differences included composition of the reference group and whether diagnostic and/or symptomatic tests were excluded from the analysis. Consensus guidelines to standardize exposure definitions are needed to ensure evaluations of cervical cancer screening can accurately measure the impact of transitioning from cytology to human papillomavirus–based screening and to allow comparisons between programs.
UR - http://www.scopus.com/inward/record.url?scp=85121735053&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-21-0376
DO - 10.1158/1055-9965.EPI-21-0376
M3 - Review article
C2 - 34526301
AN - SCOPUS:85121735053
SN - 1055-9965
VL - 30
SP - 2154
EP - 2166
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 12
ER -